Payment overview · 2025
General Payments
$71.24
4 reported records · 3 companies
Healthcare provider profile · identity verified
Tammy Renee Gilbert
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LOUISVILLE, KY · NPI 1699233684
Verified facts
What the public records show
CMS Open Payments records show Tammy Renee Gilbert received $71.24 in general payments during 2025 across 4 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 41.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid, Rexulti.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nuplazid by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.41 | 41.3% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.86 | 36.3% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.97 | 22.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $71.24 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.41 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.86 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $15.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Sertraline Hcl | Sertraline Hcl | 339 | 44 |
| Mirtazapine | Mirtazapine | 313 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 269 | 48 |
| Eliquis | Apixaban | 254 | 29 |
| Gabapentin | Gabapentin | 233 | 28 |
| Potassium Chloride | Potassium Chloride | 197 | 32 |
| Furosemide | Furosemide | 188 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 185 | 48 |
| Buspirone Hcl | Buspirone Hcl | 168 | 28 |
| Tramadol Hcl | Tramadol Hcl | 164 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 161 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 152 | 25 |
| Divalproex Sodium | Divalproex Sodium | 140 | 15 |
| Omeprazole | Omeprazole | 134 | 25 |
| Donepezil Hcl | Donepezil Hcl | 127 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 33 |
| Famotidine | Famotidine | 112 | 16 |
| Jardiance | Empagliflozin | 109 | suppressed |
| Memantine Hcl | Memantine Hcl | 105 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 22 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 99 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 90 | 27 |
| Lisinopril | Lisinopril | 83 | 13 |
| Trazodone Hcl | Trazodone Hcl | 83 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 42 |
| Linzess | Linaclotide | 80 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 13 |
| Losartan Potassium | Losartan Potassium | 74 | 12 |
| Baclofen | Baclofen | 71 | suppressed |
| Prednisone | Prednisone | 71 | 31 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 66 | 35 |
| Myrbetriq | Mirabegron | 66 | suppressed |
| Metformin Hcl | Metformin Hcl | 65 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 42 |
| Olanzapine | Olanzapine | 57 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 56 | suppressed |
| Constulose | Lactulose | 55 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 21 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 52 | suppressed |
| Ssd | Silver Sulfadiazine | 52 | 13 |
| Nystatin | Nystatin | 50 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Phenytoin | Phenytoin | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 44 | suppressed |
| Simvastatin | Simvastatin | 44 | suppressed |
| Fluconazole | Fluconazole | 43 | 30 |
| Erythromycin | Erythromycin Base | 42 | 13 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Vascepa | Icosapent Ethyl | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Nystop | Nystatin | 40 | 22 |
| Mupirocin | Mupirocin | 39 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 15 |
| Carvedilol | Carvedilol | 36 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Cefdinir | Cefdinir | 35 | 25 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 13 |
| Azithromycin | Azithromycin | 27 | 20 |
| Risperidone | Risperidone | 27 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 26 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Nuplazid | Pimavanserin Tartrate | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lactulose | Lactulose | 21 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Enulose | Lactulose | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 18 | 15 |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 11 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 12 |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Secuado | Asenapine | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Permethrin | Permethrin | 14 | 11 |
| Primidone | Primidone | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | 12 |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $71.24 · 4 records | Otsuka America Pharmaceutical, Inc. | INGREZZA, NUPLAZID, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error